You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 6, 2025

CLINICAL TRIALS PROFILE FOR GLUCARPIDASE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for glucarpidase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018967 ↗ Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate Completed Children's Oncology Group N/A 1993-11-01 RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system toxic effects in patients given an accidental overdose of intrathecal methotrexate.
NCT00018967 ↗ Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate Completed National Cancer Institute (NCI) N/A 1993-11-01 RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system toxic effects in patients given an accidental overdose of intrathecal methotrexate.
NCT00219791 ↗ Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance Completed BTG International Inc. Phase 2 2000-01-01 To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.
NCT00424645 ↗ Voraxaze for Delayed Methotrexate Clearance Terminated BTG International Inc. Phase 1/Phase 2 2007-01-01 Primary Objectives: 1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of methotrexate (MTX) clearance following high dose MTX treatment in patients with a delayed MTX clearance. 2. To evaluate the pharmacokinetics (PK) of Glucarpidase following high dose MTX treatment in patients with a delayed MTX clearance. 3. To evaluate the safety profile of Glucarpidase following high dose MTX treatment in patients with a delayed MTX clearance. Secondary Objectives: 1. To evaluate the effect of Glucarpidase on the incidence of neutropenic fever and use of intravenous (IV) antibiotics. 2. To evaluate the effect of Glucarpidase on the length of hospitalization. 3. To evaluate the effect of Glucarpidase on renal function. 4. To evaluate the effect of Glucarpidase on Quality of Life (QOL). 5. To evaluate the anti-glucarpidase antibody response. 6. To evaluate the efficacy of Glucarpidase following its use in repeated cycles of high dose MTX treatment.
NCT00424645 ↗ Voraxaze for Delayed Methotrexate Clearance Terminated M.D. Anderson Cancer Center Phase 1/Phase 2 2007-01-01 Primary Objectives: 1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of methotrexate (MTX) clearance following high dose MTX treatment in patients with a delayed MTX clearance. 2. To evaluate the pharmacokinetics (PK) of Glucarpidase following high dose MTX treatment in patients with a delayed MTX clearance. 3. To evaluate the safety profile of Glucarpidase following high dose MTX treatment in patients with a delayed MTX clearance. Secondary Objectives: 1. To evaluate the effect of Glucarpidase on the incidence of neutropenic fever and use of intravenous (IV) antibiotics. 2. To evaluate the effect of Glucarpidase on the length of hospitalization. 3. To evaluate the effect of Glucarpidase on renal function. 4. To evaluate the effect of Glucarpidase on Quality of Life (QOL). 5. To evaluate the anti-glucarpidase antibody response. 6. To evaluate the efficacy of Glucarpidase following its use in repeated cycles of high dose MTX treatment.
NCT00634322 ↗ High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma Terminated M.D. Anderson Cancer Center Phase 2 2008-10-01 The purpose of this study is to demonstrate whether use of glucarpidase facilitates administration of the next cycle of chemotherapy as scheduled and improves safety and tolerability of HDMTX given with LV
NCT00634322 ↗ High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma Terminated BTG International Inc. Phase 2 2008-10-01 The purpose of this study is to demonstrate whether use of glucarpidase facilitates administration of the next cycle of chemotherapy as scheduled and improves safety and tolerability of HDMTX given with LV
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for glucarpidase

Condition Name

Condition Name for glucarpidase
Intervention Trials
Osteosarcoma 3
Lymphoma 2
Neurotoxicity 2
Mucositis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for glucarpidase
Intervention Trials
Lymphoma 4
Osteosarcoma 3
Neurotoxicity Syndromes 2
Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for glucarpidase

Trials by Country

Trials by Country for glucarpidase
Location Trials
United States 49
Canada 7
United Kingdom 2
Australia 2
Iceland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for glucarpidase
Location Trials
Pennsylvania 3
New York 3
Minnesota 2
Florida 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for glucarpidase

Clinical Trial Phase

Clinical Trial Phase for glucarpidase
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for glucarpidase
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Terminated 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for glucarpidase

Sponsor Name

Sponsor Name for glucarpidase
Sponsor Trials
BTG International Inc. 6
University College, London 2
National Cancer Institute (NCI) 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for glucarpidase
Sponsor Trials
Other 25
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Glucarpidase

Introduction

Glucarpidase, marketed as Voraxaze, is a crucial enzyme used to treat delayed methotrexate (MTX) elimination, a condition that can lead to severe complications in patients undergoing high-dose methotrexate therapy. Here, we delve into the recent clinical trials, market analysis, and future projections for this vital drug.

Clinical Trials and Efficacy

Phase II Studies

Recent clinical trials have reaffirmed the efficacy of glucarpidase in reducing plasma MTX concentrations. A phase II investigator-initiated trial (CPG2-PII study) conducted in Japan demonstrated that glucarpidase significantly reduced MTX levels, with a clinical important reduction (CIR) rate of 76.9%[1].

Another study, the OP-07-001 trial, showed a median reduction rate of plasma MTX concentration of 98.83% just 20 minutes after glucarpidase administration[1]. These findings align with previous US studies, highlighting the drug's consistent efficacy across different patient populations.

Real-World Data and Target Trial Emulation

A comprehensive study using data from 28 major U.S. cancer centers employed a target trial emulation method to assess the clinical benefits of glucarpidase. This approach mimicked the conditions of a randomized clinical trial and revealed that patients who received glucarpidase had a 2.7-fold increase in the chances of kidney recovery compared to those who did not receive the treatment. Additionally, glucarpidase treatment was associated with faster kidney recovery and a lower risk of severe neutropenia and liver toxicity[4][5].

Safety and Tolerability

The safety profile of glucarpidase has been favorable in clinical trials. Common adverse events reported include hypersensitivity, increased blood bilirubin, and headache, but these are generally manageable[1][2].

Economic Value and Market Analysis

Cost-Benefit Analysis

Despite its efficacy, the cost of glucarpidase can be a barrier to its use. However, economic analyses suggest that the benefits of glucarpidase outweigh the costs. A decision tree model comparing glucarpidase with other treatments for delayed MTX elimination due to impaired renal function showed that timely administration of glucarpidase within 60 hours could significantly reduce healthcare costs and improve patient outcomes[2].

Market Size and Growth

The U.S. clinical trials market, which includes trials for drugs like glucarpidase, is projected to grow significantly. The market was valued at USD 25.81 billion in 2023 and is expected to reach USD 41.57 billion by 2033, growing at a CAGR of 4.88% during the forecast period. The oncology segment, where glucarpidase is primarily used, accounts for the largest revenue share and is anticipated to register the fastest CAGR[3].

Market Dynamics and Drivers

Oncology Segment

The oncology segment is a major driver for the clinical trials market, and glucarpidase plays a critical role in this area. High-dose methotrexate therapy is a standard treatment for various malignant tumors, and the need for effective antidotes like glucarpidase is paramount. The growing demand for innovative cancer therapies and the increasing focus on personalized medicine are key factors driving the growth of the oncology segment[3].

Regulatory Environment

The FDA's stringent protocols and guidance shape the parameters of clinical trials, ensuring safety and efficacy. The approval of glucarpidase in 2012 by the FDA is a testament to its rigorous evaluation process. However, as noted by Dr. David E. Leaf, "FDA approval is only the first step. If people aren't using the drug, then patients aren't benefiting from it," highlighting the need for increased adoption based on evidence-based data[5].

Future Projections

Increased Adoption

Studies have consistently shown that glucarpidase offers significant clinical benefits, including rapid reduction of MTX levels and improved kidney recovery. As more evidence emerges, it is likely that the use of glucarpidase will become more widespread, especially in settings where high-dose methotrexate therapy is common[4][5].

Economic Impact

The economic value of glucarpidase is expected to become more apparent as its use becomes more standardized. By reducing the need for prolonged hospital stays and minimizing the incidence of severe adverse events, glucarpidase can significantly lower healthcare costs in the long term[2].

Key Takeaways

  • Efficacy: Glucarpidase has been shown to rapidly reduce plasma MTX concentrations and improve kidney recovery in patients with delayed MTX elimination.
  • Safety: The drug has a favorable safety profile, with manageable adverse events.
  • Economic Value: Despite its high cost, glucarpidase offers significant economic benefits by reducing healthcare costs associated with prolonged hospital stays and adverse events.
  • Market Growth: The oncology segment, where glucarpidase is primarily used, is expected to drive growth in the clinical trials market.
  • Regulatory Approval: FDA approval in 2012 and subsequent studies have reinforced the clinical benefits of glucarpidase.

FAQs

What is glucarpidase used for?

Glucarpidase is used to treat delayed methotrexate (MTX) elimination, a condition that can occur in patients undergoing high-dose methotrexate therapy.

How does glucarpidase work?

Glucarpidase converts MTX in the blood into inactive metabolites within 15 minutes of its administration, thereby reducing the risk of MTX-induced toxicity.

What are the common adverse events associated with glucarpidase?

Common adverse events include hypersensitivity, increased blood bilirubin, and headache.

Is glucarpidase cost-effective?

Despite its high cost, economic analyses suggest that glucarpidase can reduce healthcare costs by minimizing the incidence of severe adverse events and reducing the need for prolonged hospital stays.

What is the current market outlook for glucarpidase?

The U.S. clinical trials market, particularly the oncology segment, is expected to grow significantly, with glucarpidase playing a critical role in this growth due to its efficacy and clinical benefits.

Sources

  1. Phase 2 study of glucarpidase in patients with delayed methotrexate elimination. PubMed, 2024.
  2. Glucarpidase to treat adults with delayed MTX elimination. Dovepress, 2023.
  3. U.S. Clinical Trials Market Size Industry Analysis Report, 2033. Biospace, 2024.
  4. Glucarpidase shows promise in treating kidney toxicity from methotrexate. News-Medical, 2025.
  5. Study finds chemotherapy antidote could improve recovery after kidney damage. ScienceDaily, 2025.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.